BetterLife Pharma

BetterLife Pharma is an emerging biotechnology company primarily dedicated to the development and commercialization of two compounds, BETR-001 and BETR-002, for the treatment of psychiatric and neurological disorders. BETR-001, which is undergoing preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative. Its uniqueness lies in the fact that it is unregulated, thus allowing for self-administration. BetterLife’s synthetic patent for BETR-001 removes regulatory hurdles, while its pending composition and method-of-use patents cover treatments for major depressive disorder, anxiety, neuropathic pain, and other psychiatric and neurological conditions.